Roche Reports Strong Mid-Year Results and Robust Pipeline Advances

Roche has announced its mid-year results, showcasing a solid performance in the first half of 2024. The company achieved an 8% increase in group sales, excluding COVID-19 impacts, with a notable 9% growth in the second quarter. This growth stems from both the pharmaceutical and diagnostics sectors, reflecting a stable business expansion. Roche also reported an 11% rise in core operating profit, driven by effective cost management and strategic resource allocation. Consequently, the group’s core operating margin saw an increase of nearly 2 percentage points. The core earnings per share (EPS) grew by 9%, and operating free cash flow also rose by 9%.

Roche’s First-Half Sales Increase by 5% with Strong Performance in Pharmaceuticals and Diagnostics

Roche’s financial report for the first half of 2024 showed group sales reaching $34.7 billion, growing 5% at constant exchange rates. Sales in the pharmaceuticals division were $26.3 billion, up 5%, with the underlying business (excluding COVID-19-related products) growing 8%. The main growth driver was the ophthalmology drug Vabysmo, with global demand increasing, especially in the United States, where sales reached $1.6 billion.

Roche’s diagnostics unit also performed well, with the underlying business growing 9% and total sales of $8.4 billion. Although sales of COVID-19-related products decreased, demand for immunodiagnostic and clinical chemistry products grew significantly, becoming the main driving force.

During the first half of 2024, Roche received several important regulatory approvals, including EU approval for Alecensa for early-stage lung cancer, a subcutaneous formulation of Ocrevus for multiple sclerosis, and a prefilled syringe form of Vabysmo to simplify dosing. Group sales are expected to achieve mid-single-digit growth in 2024 and core earnings per share (EPS) to maintain high growth.

Roche Reports Mid-Year Gains with Strong Pharmaceutical Sales and Updated Forecasts

Roche is revising its full-year projections upward and now expects mid-single-digit growth across both its pharmaceuticals and diagnostics divisions.

The company also forecasts a high-single-digit increase in core EPS. The top performers in Roche’s portfolio were Ocrevus (ocrelizumab), used for multiple sclerosis, and Hemlibra (emicizumab-kxwh) for hemophilia A, which saw growth rates of 8% and 7%, respectively. Vabysmo, which received a label expansion for retinal vein occlusion in October 2023, generated nearly $1.8 billion in the first half of 2024, marking an impressive 93% year-on-year increase.

In a notable development, Roche announced the discontinuation of SPK-3006, an investigational gene therapy for Pompe disease. Originally developed by Spark Therapeutics, which Roche acquired in 2019, SPK-3006 was in Phase II trials before the decision to halt its development.

Key Milestones in the EU and US, Obesity Project Pipeline, and AI-Driven Strategic Initiatives

In terms of significant milestones, Roche obtained key regulatory approvals and launched several new products. The pharmaceutical segment saw the European Union approve Ocrevus for subcutaneous administration in multiple sclerosis and Alecensa for adjuvant treatment in non-small cell lung cancer. Additionally, the U.S. granted approval for Vabysmo prefilled syringes and PiaSky in paroxysmal nocturnal hemoglobinuria. Roche advanced its regulatory filings for Susvimo in macular degeneration and diabetic retinopathy, and secured European Union filings for Elevidys in Duchenne muscular dystrophy and inavolisib, with anticipated approval by November. The company’s diagnostics division also made significant strides, with new launches including the cobas Liat Respiratory Panel and the continuous glucose monitoring system for diabetes care.

Transitioning to Roche’s project pipeline, the company highlighted several upcoming developments and product launches. Notably, Roche is advancing its obesity treatments, with new data expected to support future growth. In diagnostics, Roche is focusing on innovations like the mass spectrometry system and next-generation sequencing, which are set to revolutionize laboratory practices. 

Roche’s strategic initiatives are geared toward sustaining long-term growth. The company has refined its 10-year goals and adjusted its group strategy to focus on high-value assays and technologies. Investments in digital health, particularly in generative AI, are also part of Roche’s strategy to strengthen its core business. 

Author

Bernice Lottering